ArticleDrug delivery and translational research2026
Intra-articular dual-targeted hydrogel co-delivering diacerein nanoparticles and ketorolac for modulating neuroimmune interplay and cartilage degeneration in osteoarthritis.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a multifactorial joint disease characterized by cartilage degradation, chronic inflammation, and persistent pain, yet current treatments provide only symptomatic relief without altering disease progression. This study aimed to develop and evaluate an intra-articular co-delivery system of diacerein (DC) using solid lipid nanoparticles (SLN) and ketorolac (KT) incorporated into a hydrogel matrix (DC-SLN gel) for synergistic cartilage protection and pain relief. SLN were optimized for particle size and polydispersity index by central composite design. In addition to zeta potential, entrapment efficiency, DSC, TEM, and stability assessment. The hydrogel composed of xanthan gum and sodium hyaluronate was characterized for rheological and in vitro release studies. In vitro release studies confirmed sustained DC release for prolonged chondroprotection and rapid KT release for acute analgesia. Therapeutic efficacy was evaluated in MIA-induced OA rats through behavioral assays, histological scoring, biochemical markers, and molecular analyses of inflammatory and chondrogenic pathways. DC-SLN/KT.gel demonstrated superior outcomes compared to free drugs or single-drug formulations. It significantly reduced pain behaviors, suppressed NF-κB, IL-1β, CCL2, and Substance P, and lowered CD68⁺ macrophage infiltration. Concurrently, it preserved collagen II, inhibited MMP-13, and upregulated SOX-9 and miR-140, restoring cartilage homeostasis. In conclusion, embedding SLN within an injectable hydrogel enabled targeted, site-specific, and sustained intra-articular drug delivery, reducing systemic exposure while enhancing efficacy. These results demonstrate the DC-SLN gel as a promising translational platform that unites targeted pain management with disease-modifying potential for advanced OA therapy.
Indexed as
Identifiers
41874937What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.